DFTX financial statements
The full income statement, balance sheet, and cash-flow statement for Definium Therapeutics Inc. (DFTX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 166M+60.0% | 104M+10.7% | 93.9M+41.5% | 66.3M-29.3% | 93.9M+184.1% | ||
| Research & development | 118M+80.2% | 65.3M+25.3% | 52.1M+44.1% | 36.2M+4.0% | 34.8M+86.7% | |
| Selling, general & administrative | 48.6M+26.0% | 38.6M-7.5% | 41.7M+38.4% | 30.2M-48.9% | 59.1M+310.2% | |
| General & administrative | 48.6M+26.0% | 38.6M-7.5% | 41.7M+38.4% | 30.2M-48.9% | 59.1M+310.2% | |
| Amortization of intangibles | 0.00-100.0% | 527K-83.3% | 3.16M-0.6% | 3.18M+21.6% | 2.62M | |
| Operating income | -166M-60.0% | -104M-10.7% | -93.9M-41.5% | -66.3M+29.3% | -93.9M-184.1% | |
| Interest expense | 5.48M+140.1% | 2.28M+148.2% | 920K | — | — | |
| Net interest income | — | — | 4.66M+212.0% | 1.50M+516.4% | -359K-118.9% | |
| Other non-operating income | -17.5M-267.1% | -4.76M-155.3% | -1.87M-119.6% | 9.54M+2912.7% | -339K+62.6% | |
| Pre-tax income | -184M-69.1% | -109M-13.5% | -95.7M-68.6% | -56.8M+39.7% | -94.2M-177.6% | |
| Income tax | 0.00 | — | — | — | -1.16M | |
| -184M-69.1% | -109M-13.5% | -95.7M-68.6% | -56.8M+39.0% | -93.0M-174.1% | ||
| Net income to common | -184M-69.1% | -109M | — | — | — | |
| -$2.06-33.8% | -$1.54+36.9% | -$2.44-32.6% | -$1.84+45.9% | -$3.40 | ||
| EPS (basic) | -$2.06-33.8% | -$1.54+36.9% | -$2.44-32.6% | -$1.84+45.9% | -$3.40 | |
| Weighted-avg shares (basic) | 89.3M+26.8% | 70.5M+79.9% | 39.2M+26.9% | 30.9M+12.7% | 27.4M | |
| Weighted-avg shares (diluted) | 89.3M+26.8% | 70.5M+79.9% | 39.2M+26.9% | 30.9M+12.7% | 27.4M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 419M+48.9% | 282M+171.1% | 104M-28.9% | 146M+6.4% | 137M+68.3% | ||
| Cash & equivalents | 258M-5.8% | 274M+174.6% | 99.7M-29.9% | 142M+6.4% | 134M+66.7% | |
| Short-term investments | 154M | 0.00 | — | — | — | |
| Prepaid expenses | 7.73M-1.9% | 7.88M+89.0% | 4.17M+6.5% | 3.91M+6.4% | 3.68M+158.0% | |
| 440M+45.7% | 302M+142.6% | 125M-26.7% | 170M+3.7% | 164M+101.2% | ||
| Goodwill | 19.9M+0.0% | 19.9M+0.0% | 19.9M+0.0% | 19.9M+0.0% | 19.9M | |
| Intangible assets | — | 0.00-100.0% | 527K-85.7% | 3.69M-46.3% | 6.87M | |
| Long-term investments | — | 0.00 | — | — | — | |
| Other non-current assets | 862K+40.6% | 613K+173.7% | 224K-32.3% | 331K | — | |
| 66.7M+71.7% | 38.8M+20.5% | 32.2M+80.2% | 17.9M+71.9% | 10.4M+246.0% | ||
| Accounts payable | 5.35M+166.0% | 2.01M-51.4% | 4.14M+95.9% | 2.11M-49.5% | 4.18M+106.6% | |
| Accrued liabilities | 20.4M+59.4% | 12.8M+10.3% | 11.6M+98.0% | 5.88M-5.7% | 6.23M+531.8% | |
| 108M+77.5% | 60.7M+30.8% | 46.4M+143.3% | 19.1M+54.6% | 12.3M+118.3% | ||
| Long-term debt | 40.6M+85.7% | 21.9M+54.7% | 14.1M | — | — | |
| Other non-current liabilities | 496K | — | 32.0K-97.3% | 1.18M-38.7% | 1.93M | |
| 332M+37.6% | 241M+209.0% | 78.1M-48.2% | 151M-0.5% | 152M+99.9% | ||
| Common stock | — | 0.00 | 0.00 | — | — | |
| Additional paid-in capital | 914M+42.9% | 640M+73.8% | 368M+6.7% | 345M+19.6% | 288M+139.8% | |
| Retained earnings | -583M-46.1% | -399M-37.4% | -290M-49.2% | -194M-41.3% | -138M-208.4% | |
| Accumulated other comprehensive income | 1.08M+32.5% | 819K+138.8% | 343K-45.3% | 627K-40.1% | 1.05M+268.3% | |
| Total liabilities & equity | 440M+45.7% | 302M+142.6% | 125M-26.7% | 170M+3.7% | 164M+101.2% | |
| Common shares issued | 98.8M+31.5% | 75.1M+82.7% | 41.1M+8.2% | 38.0M+35.0% | 28.1M | |
| Common shares outstanding | 98.8M+31.5% | 75.1M+82.7% | 41.1M+8.2% | 38.0M+35.0% | 28.1M | |
| Shares outstanding (cover) | 99.7M+32.3% | 75.4M+82.3% | 41.3M+8.6% | 38.1M+35.3% | 28.1M | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -132M-66.3% | -79.1M-22.9% | -64.4M-28.4% | -50.1M-9.4% | -45.8M-94.2% | ||
| Intangible amortization | 0.00-100.0% | 527K-83.3% | 3.16M-0.6% | 3.18M+21.6% | 2.62M | |
| Deferred income taxes | — | — | — | — | -1.16M | |
| Change in payables | 3.34M+257.0% | -2.13M-205.0% | 2.02M+198.5% | -2.06M-260.4% | 1.28M+135.7% | |
| -152M | 0.00 | — | — | -297K | ||
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 297K | |
| Purchases of investments | 268M | 0.00 | — | — | — | |
| Sales/maturities of investments | 117M | 0.00 | — | — | — | |
| 267M+5.6% | 253M+1058.9% | 21.8M-63.0% | 59.1M-40.2% | 98.8M+2.2% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00-100.0% | 984K-86.9% | 7.53M-82.2% | 42.3M-48.4% | 81.9M+13.8% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -15.9M-109.1% | 174M+510.1% | -42.4M-593.3% | 8.60M-83.9% | 53.4M-27.2% | |
| Interest paid | 5.34M+140.0% | 2.22M+316.5% | 534K | — | — | |
| Income taxes paid | 0.00 | — | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.33B+154.5% | 525M+257.5% | 147M+77.5% | 82.7M-85.8% | 582M | |
| P/B | 4.0×+84.9% | 2.2×+42.1% | 1.5×+184.1% | 0.5×-86.0% | 3.8× | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: DFTX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all DFTX filings on SEC EDGAR → Not investment advice.